Home  »  Finance   »  Citius Pharmaceuticals Inc. (NASDAQ: CTXR) Could F...

Citius Pharmaceuticals Inc. (NASDAQ: CTXR) Could Fell Another -627.27%

The trading price of Citius Pharmaceuticals Inc. (NASDAQ:CTXR) closed lower on Tuesday, May 23, closing at $1.10, -2.65% lower than its previous close.

Traders who pay close attention to intraday price movement should know that it fluctuated between $1.07 and $1.16. In examining the 52-week price action we see that the stock hit a 52-week high of $1.71 and a 52-week low of $0.77. Over the past month, the stock has lost -24.66% in value.

Unlock the Hottest Top 10 Penny Stocks Today! Discover Now

Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.

Gain Access to Top 10 Penny Stocks Now!.


Citius Pharmaceuticals Inc., whose market valuation is $167.33 million at the time of this writing, is expected to release its quarterly earnings report Aug 09, 2023 – Aug 14, 2023. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by -$0.04 per share this quarter, however they have predicted annual earnings per share of -$0.16 for 2023 and $0.43 for 2024. It means analysts are expecting annual earnings per share growth of 30.40% this year and 368.70% next year.

From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue in 2023 is $370k.

A company’s earnings reviews provide a brief indication of a stock’s direction in the short term, where in the case of Citius Pharmaceuticals Inc. No upward and no downward comments were posted in the last 7 days. On the technical side, indicators suggest CTXR has a 50% Buy on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 50% Buy, while an average of long term indicators suggests that the stock is currently 50% Sell.

Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned CTXR a recommendation rating is 3. Out of them, 0 rate it a Hold, while 3 recommend Buy, whereas 0 assign an Overweight rating. 0 analyst(s) have tagged Citius Pharmaceuticals Inc. (CTXR) as Underweight, while 0 advise Sell. Analysts have rated the stock Buy, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.

A quick review shows that CTXR’s price is currently -16.54% off the SMA20 and -14.31% off the SMA50. The RSI metric on the 14-day chart is currently showing 38.73, and weekly volatility stands at 9.25%. When measured over the past 30 days, the indicator reaches 9.01%. Citius Pharmaceuticals Inc. (NASDAQ:CTXR)’s beta value is currently sitting at 1.41, while the Average True Range indicator is currently displaying 0.12. With analysts defining $4.00-$8.00 as the low and high price targets, we arrive at a consensus price target of $6.00 for the trailing 12-month period. The current price is about -263.64% off the estimated low and -627.27% off the forecast high, based on this estimate. Investors will be thrilled if CTXR’s share price rises to $6.00, which is the median consensus price. At that level, CTXR’s share price would be -445.45% below current price.

To see how Citius Pharmaceuticals Inc. stock has been performing in comparison to its peers in the industry, here are the numbers: CTXR stock’s performance was -2.65% in the latest trading, and 20.23% in the past year. Another comparable company Omeros Corporation (OMER) saw its stock close -3.76% lower in the most recent trading session but was up 118.86% in a year. Also in last trading session, the S&P 500 Index has plunged -1.12%, while the Dow Jones Industrial also saw a negative session, down -0.69% on the day.

An evaluation of the daily trading volume of Citius Pharmaceuticals Inc. (NASDAQ:CTXR) indicates that the 3-month average is 1.37 million. However, this figure has increased over the past 10 days to an average of 3.27 million.

Currently, records show that 146.25 million of the company’s shares remain outstanding. The insiders hold 8.40% of outstanding shares, whereas institutions hold 11.10%. The stats also highlight that short interest as of Apr 27, 2023, stood at 13.6 million shares, resulting in a short ratio of 10.65 at that time. From this, we can conclude that short interest is 9.30% of the company’s total outstanding shares. It is noteworthy that short shares in April were up slightly from the previous month’s figure, which was 11.97 million. However, since the stock’s price has seen 39.24% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.

Leave a Comment

Your email address will not be published. Required fields are marked *